Amazon Pharmacy Wegovy Oral Pill Price Hits $149 in Bold Healthcare Move
Amazon Pharmacy now offers Novo Nordisk’s oral Wegovy pill starting at $149 for cash-paying patients. Discover how this impacts the healthcare market.
$149 is the new entry price for weight loss. Amazon Pharmacy just added Novo Nordisk’s Wegovy oral pill to its digital lineup, signaling a massive shift in how Americans access GLP-1 treatments. It's a game-changer for patients who've long dreaded weekly injections or struggled with the high costs of obesity care.
Amazon Pharmacy Wegovy Oral Pill Price and Accessibility
According to Reuters, eligible customers with insurance can now pay as little as $25 for a one-month supply. For those paying cash, the starting price is $149 per month—one of the lowest entry points in the booming weight loss market. Amazon isn't stopping at home delivery; in the coming weeks, it plans to stock these pills in prescription kiosks at select One Medical clinics.
Disrupting the Multitrillion-Dollar Healthcare Market
Amazon's push into healthcare has been years in the making. It began with the $750 million acquisition of PillPack in 2018 and accelerated with the $3.9 billion buyout of One Medical in 2022. Now, analysts estimate the pharmacy service generates roughly $2 billion in annual revenue. By partnering with Novo Nordisk and Eli Lilly, Amazon is positioning itself as the logistics backbone of the GLP-1 era.
The competition is heating up. While Novo's pill is now available at 70,000 locations including Costco and CVS, Eli Lilly is expected to launch its own oral rival later in 2026. This battle for 'oral dominance' could significantly lower barriers for millions of needle-phobic patients.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Teal Hazel, Novo Nordisk's head of US public affairs, is resigning amid intense pressure over Ozempic and Wegovy pricing. Read more on the impact on lobbying strategy.
Novo Nordisk slashes Wegovy prices in China to fight off competition from Eli Lilly and local firms. Discover the impact on the $20B Chinese obesity market.
Discover the future of GLP-1 weight-loss pills in 2026. From oral medication to TikTok influencers and telehealth apps, see how the market is changing.
Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.
Teal Hazel, Novo Nordisk's head of US public affairs, is resigning amid intense pressure over Ozempic and Wegovy pricing. Read more on the impact on lobbying strategy.
Novo Nordisk slashes Wegovy prices in China to fight off competition from Eli Lilly and local firms. Discover the impact on the $20B Chinese obesity market.
Discover the future of GLP-1 weight-loss pills in 2026. From oral medication to TikTok influencers and telehealth apps, see how the market is changing.
Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.